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Abstract: Increasing evidence links atherosclerosis to a decreased bone thickness. This correlation could reflect a 
bone/plaque interaction. Hereby we analyzed Hounsfield density (HU) and mineral turnover in bone and in the arte-
rial calcifications (AC), using a computational method applied to PET/CT data. 79 18F-NaF PET/CT from patients with 
AC were retrospectively analyzed. Mean AC density and background-corrected uptake (TBR) were estimated after 
semi-automatic isocontour segmentation. The same values were assessed in the trabecular bone, using an auto-
matic adaptive thresholding method. Patients were then stratified into terciles, according to their mean HU plaque 
density (“light”, “medium” or “heavy” calcifications”). 35 18F-NaF PET/CT from patients without AC served as con-
trols. Vertebral density and TBR were lower in patients than in controls (137±25 vs. 160±14 HU, P<0.001); (6.2±3.9 
vs. 8.4±3.4, P<0.05). Mean trabecular TBR values were 8.3±4, 4.5±2.1 and 3.5±1.8 in light, medium and heavy 
AC groups, respectively (P<0.05 for light vs. medium and P<0.01 for light vs. heavy). Similarly, mean trabecular HU 
was 143±19, 127±26 and 119±18 in the three groups, respectively (P<0.01 for light vs. heavy). Mean AC density 
was inversely associated with the trabecular HU (R=-0.56, P<0.01). Conversely, plaques’ TBR directly correlated 
with the one in trabecular bone (R=0.63, P<0.001). At multivariate analysis, the sole predictor of vertebral density 
was plaque HU (P<0.05). Our data highlight a correlation between plaque and bone morpho-functional parameters 
and suggest that observing skeletal bone characteristics could represent a novel window on atherosclerosis patho-
physiology.
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Introduction
Cardiovascular disease is a widespread health 
problem, causing more mortality and morbidity 
than any other disease, not only in advanced 
economies but also in emerging middle-low 
income countries [1]. The hallmark of this ail-
ment is atherosclerosis; there is now over-
whelming evidence that these lesions do begin 
at a very early age and that the plaque build-up 
process spans over decades [2-5]. Evolution of 
atherosclerotic plaques can, however, occur at 
a variable rate, according to presence, degree, 
and duration of risk factors. Radiological evi-
dence of calcification is a relatively late hall-
mark of vascular lesions, representing an 
advanced stage of disease progression as well 
as a marker of increased morbidity risk [6]. 
However, there are accumulating data suggest-
ing that processes leading to calcification could 
begin early in the plaque’s natural history [7, 8]; 
moreover, patients with elevated cardiovascu-
lar risk profile appear having a higher mineral 
turnover within the vascular wall of large and 
small vessels [9-11].
This evidence fosters the concept of the athero-
sclerotic disease as a systemic, rather than a 
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local, ailment, in which whole-body modifica-
tions promote a “plaque-promoting” environ-
ment [12-17]. Calcification represents the late 
stages of plaque evolution, in which the athero-
sclerotic lesion becomes apparent at x-ray-
based imaging. Remarkably, the same molecu-
lar mediators of arterial calcifications, such as 
those belonging to the RANKL-RANK-Osteopro- 
tegerin axis [15, 16], are also involved in bone 
turnover and can influence bone density: acting 
on RANKL with a specific inhibitor has proved 
effective in halting and even reversing osteopo-
rosis [18].
Accordingly, it has been proposed that plaque 
build-up and osteoporotic degeneration might 
be mediated by common factors [19, 20]. This 
hypothesis is supported by the evidence that 
the degree of arterial calcification is linked to 
progressive loss of bone density as well as to 
increased fracture risk [21, 22]. It could be 
hypothesized that, in the scenario of diffuse 
atherosclerotic disease, the presence of inflam-
mation may release specific mediators, which 
could stimulate an acceleration in mineral turn-
over even in areas remote to the plaques [15, 
23]. Such a mechanism could explain the 
increased plaque calcium deposition and the 
impoverishment of the bone mineral density 
that is observed in these subjects.
In this sense, the status of bone density could 
represent a window on the processes of an 
ongoing arterial calcification process; more-
over, interventions aimed at restoring bone 
density could also take effect on the plaque’s 
build-up. 
Testing this hypothesis requires a method able 
to detect both calcium density and mineral 
metabolism at the same time. The technologi-
cal development of hybrid imaging, comprising 
multi-detector CT and 3D-positron-emission 
tomography (PET/CT) might allow for such ev- 
aluations [24]. An ever-increasing number of 
reports have described the exploitation of 
18F-Natrium-Fluoride (18F-NaF) to detect calci-
um deposition within the actively growing pl- 
aque [25-28]. Our previous experience showed 
that this approach has a more significant valid-
ity in the earlier stages of plaque formation, 
while the calcification pathways are most active 
[7, 15]. In the present study, 18F-NaF-PET/CT 
images were analyzed with a two-way approach: 
measurement of mineral metabolism and calci-
fication density within plaques, as well as in tra-
becular bone. In doing so, we tested the hypoth-
esis that increased plaque density is linked 
with loss of bone mineral content and that the 
activation of mineral metabolism within the 
atherosclerotic plaque is paralleled by a similar 
activation in the trabecular bone.
Materials and methods
Patient populations
The study included 79 patients with either 
breast (65%) or prostate (35%) cancer undergo-
ing 18F-NaF PET/CT scan for suspected bone 
metastases or for monitoring of known ones. 
Patients were included in the analysis if they 
presented at least one CT-evident arterial calci-
fication (AC) in the infrarenal abdominal aorta. 
AC was defined as a mural area of calcium 
deposition, with a minimum HU of 130 and evi-
dent in at least five consecutive CT slices [26]. 
This size requirement was chosen to avoid a 
partial-volume effect in the evaluation of PET 
uptake.
Exclusion criteria were: history of vasculitis, 
autoimmune or systemic inflammatory disease 
as well as chemo- or radiotherapy in the pre-
ceding 8 weeks, as previously proposed [9]. 
Chronic steroid therapy represented an addi-
tional exclusion factor. Cardiovascular risk pro-
file was assessed in each patient (including 
age, sex, diabetes, smoking, hypertension, dys-
lipidemia and body mass index).
35 age- and sex-matched patients, having no 
evidence of arterial calcifications were random-
ly selected from our pool of 18F-NaF-PET/CT 
examinations and used as plaque-free con- 
trols.
Written informed consent was obtained from 
each patient before the exam, including the 
permission to use pseudonomyzed imaging 
data for research purpose. Institutional Ethics 
Committee approved this retrospective study 
and the requirement to obtain additional 
informed consent for this specific analysis was 
waived. 
18F-NaF PET/CT acquisition and images recon-
struction
Patients underwent 18F-NaF PET/CT using two 
16 slices PET/CT hybrid systems: (1) Biograph 
18F-NaF uptake in plaque and bone
389 Am J Nucl Med Mol Imaging 2018;8(6):387-396
16 (Siemens Medical Solutions, Knoxville TN, 
United States); and (2) Discovery LS (GE Me- 
dical Systems, Milwaukee, WI, United States). 
In both cases patients received an intravenous 
bolus injection of 18F-NaF (4.8-5.2 MBq per 
kilogram of body weight). PET/CT acquisition 
started 60-75 min thereafter, in the meantime 
the patient was hydrated and encouraged to 
void, as to diminish the unbound tracer frac-
tion. The entire body was scanned from vertex 
to toes in an “arms down” position; emission 
scan lasted 120 seconds per bed position. PET 
raw data were reconstructed by means of 
ordered subset expectation maximization 
(OSEM, 3 iterations, 16 subsets) and attenua-
tion correction was performed using CT data. 
The transaxial field of view and pixel size of the 
reconstructed PET images were 58.5 cm and 
4.57 mm, respectively, with a matrix size of 
128 × 128 mm. As per standard PET/CT imag-
ing protocol, 16-detector row helical CT scan 
was performed with non-diagnostic current and 
voltage settings (120 Kv, 80 mA), with a gantry 
rotation speed of 0.5 s and table speed of 24 
mm per gantry rotation. No contrast medium 
was injected. The entire CT dataset was fused 
with the 3-dimensional PET images using an 
integrated software interface (Syngo; Siemens 
Erlangen, Germany). Low dose CT (reconstruct-
ed at 4 mm thick slices) was used for anatomi-
cal reference for the localization of vascular 
calcification. 
Plaque analysis 
Image analysis was carried out with 64-bit 
Osirix DICOM viewer (Pixmeo, Geneva, CH) and 
with PMOD software package (v. 3.4, PMOD 
Technologies, Zurich, CH). ACs were excluded 
from the analysis if there was considerable sus-
pect of spill-over from a nearby structure (e.g. 
lumbar vertebrae). In case of doubt, a safety 
margin of 1-cm from the bone edge was used.
For both CT and PET aortic measurements the 
whole aorta was considered, including the 
ascending, descending and infrarenal seg-
ments. CT images were used to semi-automati-
cally draw volumes of interest (VOI) on each AC 
site, using a region-growing algorithm, whose 
lower limit was set at 130 HU. In each VOI, aver-
age HU was calculated. In addition, an Agatston-
like calcium score (CS) was calculated with a 
dedicated software application (Osirix DICOM 
viewer, Pixmeo, Geneva, CH). Thereafter, aver-
age SUV was computed in each VOI using the 
co-registered PET data. These values were nor-
malized for blood-pool radioactivity, which was 


















Age, years 70.8±8.04 70.5±10.5 70.9±7.17 72.4±6.1 NS NS
Women 65% 89% 57% 45% 0.009 NS
Previous chemotherapy 41% 11% 51% 62% 0.002 0.045
Previous radiotherapy 55% 32% 63% 65% 0.02 NS
Previous chemo- or radiotherapy 63% 32% 73% 81% 0.001 0.039
Previous chemo- and radiotherapy 29% 11% 35% 43% 0.04 NS
Body mass index, kg/m2 25.3±4.6 26.9±3.6 24.8±4.8 23.2±2.8 NS NS
Obese (body mass index ≥30 kg/m2) 9% 16% 7% 6% NS NS
Smoking history 58% 57% 58% N/A NS -
Hypertension 67% 69% 65% N/A NS -
Antihypertensive medications 66% 77% 61% N/A NS -
Dyslipidemia 46% 43% 47% N/A NS -
Lipid-lowering medications 25% 31% 24% N/A NS -
Diabetes 29% 50% 21% N/A 0.03 -
Bisphosphonates 7% 0% 7% N/A NS -
Warfarin 7% 0% 7% N/A NS -
Proton pump inhibitors 31% 29% 31% N/A NS -
WB: Whole-body.
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Figure 1. Density trabecular bone and in the aortic plaque. In the three 
top panels are displayed low-dose CT images depicting examples of typical 
“light”, “medium” and “heavy” plaques. Directly below (middle panels) are 
displayed CT slices of the trabecular bone from the same patients. After ter-
ciles stratification according to mean plaque density, subjects with a higher 
mean plaque thickness presented a decreased vertebral density and me-
tabolism (lower histogram).
obtained by drawing a 10-slice thick VOI on the 
inferior vena cava, to obtain plaque target-to-
background ratio (TBR). 
Computational analysis of trabecular bone
Bone image analysis was performed semi-auto-
matically according to a previously validated 
method [29-32]. Briefly, the algorithm identifies 
the skeleton on CT images assuming that co- 
mpact bone is the structure with the highest 
radiograph attenuation coefficient in the hu- 
man body. Once it has identified the skeletal 
border, the program starts the thresholding al- 
gorithm, which samples a 2-voxel-thick layer 
and computes its average Hounsfield Unit (HU) 
value. Thereafter, all skeletal voxels having at- 
ally removed all bone regions with suspicious 
metastatic involvement.
Statistical analysis 
All data are reported as Mean ± SD. Patients 
with ACs were stratified in three groups accord-
ing to their tercile of mean plaque density: 
patient with a mean calcification in the lower 
tercile were defined as with “light” calcifica-
tions, while those in the middle and upper ter-
ciles were defined as having “medium” and 
“heavy” calcifications, respectively. Differences 
between groups were tested using one-way 
analysis of variance, with intergroup compari-
son afforded using Bonferroni test. Correlation 
was tested used bivariate analysis (Pearson’s R 
tenuation coefficient equal or 
above this value are consid-
ered as compact bone, and 
the remaining as trabecular 
bone. This latter volume is th- 
en voxel-wise multiplied again- 
st the PET co-registered da- 
ta to extract and represent 
bone marrow metabolic activ-
ity. For the purpose of the 
present analysis, thoracic and 
lumbar vertebrae were select-
ed as representative bone 
regions.
This above-described segme- 
ntation method can tell apart 
osteoblastic metastases from 
normal trabecular bone [33]. 
Moreover, the software rem- 
oves all voxels under a 100 
HU threshold, effectively ex- 
cluding lytic metastases. Th- 
erefore, it is possible to ana-
lyze trabecular bone metabo-
lism without the influence of 
uptake from tumor localiza-
tions. However, effects due to 
radioactivity spill-over from 
nearby lesion or presence of 
mixed-type metastases within 
trabecular bone cannot be 
denied with utmost security by 
the automated analysis. For 
this reason, two expert read-
ers (SM and GMS) reviewed 
the output images and manu-
18F-NaF uptake in plaque and bone
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as well as by multiple linear regression analy-
sis. p values <0.05 were considered as statisti-
cally significant. Statistical analyses were per-
formed using SPSS software Advanced Models 
24 (IBM, Chicago, Illinois, US).
Results
Characteristics of the study population
Out of the 79 study patients, 60 (76%) had evi-
dence of bone localizations while 19 (24%) had 
no highlightable metastases. Table 1 lists the 
main characteristics of the study population, 
including a comparison of patients with and 
without bone metastases. The prevalence of 
major cardiovascular risk factors and medica-
tions did not differ between these groups, 
except for a slightly higher prevalence of diabe-
tes in those without bone metastases (50% vs. 
21% in those with metastases, P=0.03). The 
only significant difference in 18F-NaF PET/
CT-derived parameters was a higher aortic 
mean HU in those patients with evidence of 
bone metastases (241.8±58.7 vs. 241.8±58.7 
in those without metastases, P=0.03). There 
were no other differences in bone-related pa- 
rameters.
mineral metabolism as well as in trabecular 
bone density can be observed when comparing 
the three subgroups, whereas patients with 
“heavy” calcifications show significantly re- 
duced values in comparison with these with 
“light” arterial calcium deposits. 
In fact, mean trabecular TBR values were 
8.3±4, 4.5±2.1 and 3.5±1.8 in light, medium 
and heavy calcifications’ groups, respectively 
(P<0.05 for light vs. medium and P<0.01 for 
light vs. heavy). Similarly, mean trabecular HU 
was 143±19, 127±26 and 119±18 in the three 
groups, respectively (P<0.01 for light vs. heavy). 
Finally, uptake intensity within the plaque dw- 
indled when progressing from heavy to light 
calcifications (TBR: 2.1±1; 1.8±1 and 1.4±0.6 
for light, medium and heavy calcifications, 
respectively, P<0.05 for medium vs. heavy and 
P<0.01 for light vs. heavy). See Figures 1, 2 
and Table 2 for details.
Interaction between plaque and bone
Mean plaque density showed an inverse asso-
ciation with vertebral HU density (R=-0.56, 
P<0.01, Figure 3). In opposition, no correlation 
Figure 2. Mineral metabolic activity in patients and controls. The histograms 
depict the target-to-background ratio of subjects with a ACs and of controls 
in trabecular bone (upper) and the corresponding value within the plaques. 
Subjects with ACs had a lower TBR than controls; however, this metabolic de-
crease was circumscribed to patients with medium and heavy calcifications. 
Likewise, plaque TBR was higher in less heavily calcified plaques.
On the basis of the tercile 
stratification, the “heavy” and 
“medium” calcifications’ grou- 
ps counted 26 patients each 
and the remaining 27 patients 
were placed in the “light” cal-
cification group.
Uptake and calcification 
indices 
In patients with ACs, mean 
TBR in the trabecular bone 
was 6.2±3.9 and mean tra-
becular bone density was 
137±25 HU. The mean TBR of 
all aortic plaques was 1.9± 
1.2, with a mean HU density 
of 227±61. Control patients 
without ACs had a marked- 
ly higher vertebral density 
(160±14 HU, P<0.001 vs. 
patients with plaques) and a 
slightly higher mineral metab-
olism (TBR 8.4±3.4, P<0.05 
vs. patients with plaques). 
Among the patients with ACs, 
a progressive reduction in 
18F-NaF uptake in plaque and bone
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Figure 3. Correlation between vertebral density and plaque features. A high-
er plaque density was associated to a lower trabecular density; conversely, 
TBR in the AC was directly associated with the one in the trabecular skeleton.
Conversely, plaque and tra-
becular bone TBR were dire-
ctly and closely correlated 
(R=0.63 and P<0.001, Figure 
3). 
Arterial plaque HU density dis-
played an inverse correlation 
with its own TBR (R=-0.42, 
P<0.05, Figure 4), as well as 
with lumbar vertebrae TBR 
(R=-0.47, P<0.01, Figure 4). 
Multiple regression analysis 
of plaque density and me-
tabolism
At univariate analysis, mean 
HU density of aortic plaque 
was not predicted by any of 
the cardiovascular risk factor 
or by age; conversely, it was 
related to its own TBR (P≤ 
0.001) as well as by trabecu-
lar bone TBR (see Table 3 for 
details). Mean vertebral den-
sity was related only to plaque 
density (P<0.05); conversely 
age, use of bisphosphonates 
and previous radio/chemo-
therapy had no influence on 
vertebral status (Table 4).
Discussion
Our results show the exis-
tence of a correlation betwe- 
en mineral metabolism in the 
arterial plaque and in the tra-
becular skeleton. This connec-
Figure 4. Correlation between plaque and trabecular mineral metabolism. 
Patients with thicker arterial calcifications showed a reduced mineral me-
tabolism within the plaque itself and in the trabecular bone.





















    Bone mean HU 137±25 135±31 126±18 160.3±14 NS <0.001
     Bone mean TBR 6.2±3.9 5.9±2 6.4±4.5 8.4±3.8 NS 0.034
Aortic plaque variables
    Aortic mean HU 227±71 206±65 245±59 - 0.026 -
    Aortic mean TBR 1.9±1.2 1.9±1.4 2±1.1 - NS -
Infrarenal aortic diameter, mm 18.6±4.4 18.1±1.6 18.8±4.9 - NS -
between age and HU density was obse- 
rved.
tion can be highlighted both on the morpholog-
ic as well as on the metabolic plane. From the 
18F-NaF uptake in plaque and bone
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morphological point of view, it was already 
established that patients with arterial calcifica-
tions suffer from reduced calcium density and 
are at increased risk for bone fractures [21, 34, 
35]. In particular, Kiel et al. analyzed patients 
from the Framingham study cohort longitudi-
nally and suggested that the association 
between arterial calcification and the bone 
mineral content reduction could be more than 
a simple age-related random association. Ac- 
tually, in our study, patients with and without 
aortic calcifications had no significant age dif-
ferences; however, the ones with calcifications 
had markedly reduced bone density. Moreover, 
patients with extended and thick arterial calcifi-
cations had a greater bone density impairment 
when compared to those with early-stage arte-
rial lesions.
From the metabolic point of view, the presence 
of calcification was related to reduce metabo- 
lic activity within the trabecular bone. Similar 
to bone density, the impairment was gre- 
thin the plaque microenvironment and relevant 
for the plaque progression, including RANKL, 
which is also a potent osteoclast activator [15, 
39], could be able to act on the remote skeletal 
tissue. On the other hand, if bone resorption 
and calcium deposition are governed by similar 
mechanisms, then contrasting bone resorption 
could have beneficial effects on arterial calcifi-
cations as well. This hypothesis has been to 
this date scarcely investigated: the only avail-
able data come from a subpopulation of the 
FREEDOM study, where the effect of a long-
lasting Denosumab (a specific RANKL antibody) 
therapy on cardiovascular risk and calcification 
progression were tested against a placebo. The 
study failed to demonstrate a cardiovascular 
benefit of the drug over a three-year period (a 
non-significant 2% reduction of cardiovascular 
risk was observed). However, this study includ-
ed the female gender only, with 91% of patients 
being older than 70 years. Moreover, the follow-
up period was limited to three years. Therefore, 
it is unknown whether this approach would be 






Beta t Lower Bound Upper Bound
Age 0.168 1.503 NS -0.407 2.91
Gender -0.033 -0.296 NS -32.12 23.813
Smoking History -0.108 -0.929 NS -29.935 10.896
Hypertension 0.032 0.271 NS -23.938 31.486
Diabetes 0.025 0.21 NS -28.048 34.648
Dyslipidaemia 0.061 0.51 NS -20.355 34.339
Aortic Plaques TBR -0.401 -3.786 <0.001 -43.009 -13.351
Mean trabecular TBR -0.558 -3.863 <0.001 -14.966 -4.641
Table 4. Multiple regression analysis of parameter influencing vertebral 
density (HU)
Variable Beta t Sig.
95% Confidence Interval for B
Lower Bound Upper Bound
Chemotherapy -.154 -.685 NS -31.308 16.077
Radiotherapy .370 1.658 NS -4.738 37.925
Bisphosphonates -.215 -1.188 NS -68.115 19.372
BMI .342 1.643 NS -.711 5.489
Age -.045 -.220 NS -1.419 1.154
Gender .247 1.15 NS -0.856 1.152
AC Density (HU) -.546 -2.671 .014 -.398 -.051
Mean trabecular TBR -.050 -.214 NS -3.347 2.737
Mean AC TBR -.105 -.331 NS -22.264 16.278
atest in the group 
with the thickest 
calcifications. Since 
the uptake of sodi-
um fluoride in the 
osseous matrix re- 
flects the rate of 
new bone forma-
tion [36-38], it may 
follow that a re- 
duced uptake is ca- 
used by a reduced 
bone-deposition ac- 
tivity or by an aug-
mented bone ero-
sion. In our series, 
the multivariate an- 
alysis showed that 
external therapy (in- 
cluding bisphosph- 
onates), age and 
BMI were not asso-
ciated with the tra-
becular thickness; 
the only relevant pr- 
edictor of bone den-
sity was the arterial 
calcification thick-
ness. It might be hy- 
pothesized that fa- 
ctors produced wi- 
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effective if applied to the male gender, if start-
ed at an earlier age or if its effects are evaluat-
ed on a more extended time-span. In fact, con-
sidering the long-term course of the athero- 
sclerotic disease, a continuous therapy might 
be in order to achieve full effect. Even if the 
anti-resorption therapy should prove unsuc-
cessful in delimiting plaque growth, it could 
nonetheless be used to prevent bone loss and 
consequently to limit the fracture risk in these 
patients [40].
Finally, there was an inverse correlation 
between plaque density and its mineral metab-
olism. This phenomenon has been already 
investigated in our previous study [7] and it’s 
likely to reflect the different stages of active 
and passive calcifications within plaques [26].
Overall, our study demonstrates a decreasing 
trend in bone density as well as in bone and 
plaque mineral metabolism, as the arterial 
plaques grow and become thicker. This pattern 
is progressive and a difference between sub-
jects with and without arterial calcifications 
can be observed in the earlier stages of vascu-
lar calcium deposition. As the disease pro-
gresses and the plaque accumulates more cal-
cium, changes within the remote bone tissue 
become steadily more pronounced. These data 
suggest that observation of bone morphologic 
and metabolic patterns could represent a win-
dow in the evaluation of the pathophysiology of 
the atherosclerotic plaque. Further studies are 
needed to determine the exact molecular 
mechanism and to test a possible way to influ-
ence the plaque progression by acting on min-
eral metabolism.
The present study is affected by some limita-
tions. It is a dual-center retrospective study, 
enrolling the only possible population for analy-
sis of 18F-NaF distribution, i.e. prostate and 
breast cancer patients, submitted to the exam 
for known or suspected metastases. While this 
has no influence on plaque uptake, the pres-
ence of skeletal localizations could have 
impacted the uptake on neighboring voxels, 
both due to the different resolution of PET and 
CT as well as for the static effect of skeletal 
metastases on healthy tissue metabolism [41, 
42]. For these reasons, a manual correction 
was used in all cases to eliminate any spillover 
artifact after the automatic bone segmenta-
tion. A further limitation is that, although we 
demonstrated a decreased trabecular density 
in patients with thicker plaques, we had neither 
DEXA scan data nor mineral metabolism blood 
values at disposal. Further prospective studies, 
enrolling patients with planned 18F-NaF PET/CT 
controls and known cardiovascular disease, 
could shed light on these aspects.
Conclusion
The present study suggests the occurrence of a 
systemic interplay between trabecular bone 
and the atherosclerotic plaque. While the deter-
minants of such correlation remain yet to be 
identified, our data highlight a progressive 
impairment of the bone structure with pro-
gressing aortal atherosclerosis. In this context, 
the bone might serve as a window on the dis-
ease status in patients with atherosclerosis. 
Further research could verify, also with preclini-
cal studies, the potential efficacy of bone-active 
drugs on the progression of the arterial plaque 
and thus possibly foster novel anti-plaque 
strategies.
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